Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Response to Calcagno comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".

Cusini A, Ledergerber B, Widmer N, Günthard HF.

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):e14-5. doi: 10.1097/QAI.0b013e3182a82281. No abstract available.

PMID:
24047974
2.

Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".

Calcagno A, D'Avolio A, Di Perri G, Bonora S.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):e118-9. doi: 10.1097/QAI.0b013e3182809d9f. No abstract available.

PMID:
24135736
3.

Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.

Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35. doi: 10.1097/QAI.0b013e318274e2b0. Erratum in: J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e170-1.

PMID:
23018371
4.

Recurrent cerebrospinal fluid escape in an HIV-1-infected patient receiving antiretroviral therapy.

Martins J, Santos E, Salgado P, Maia L, Dias D, Marta M, França M.

AIDS. 2016 Apr 24;30(7):1143-4. doi: 10.1097/QAD.0000000000001037. No abstract available.

PMID:
27028145
5.

Emergence of raltegravir-resistant HIV-1 in the central nervous system.

Watanabe K, Honda M, Watanabe T, Tsukada K, Teruya K, Kikuchi Y, Oka S, Gatanaga H.

Int J STD AIDS. 2010 Dec;21(12):840-1. doi: 10.1258/ijsa.2009.009283.

PMID:
21297097
6.

Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.

Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, Niang M, Mille C, Le Moal G, Viard JP, Rouzioux C; AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS).

J Antimicrob Chemother. 2013 May;68(5):1169-78. doi: 10.1093/jac/dks533. Epub 2013 Jan 20.

PMID:
23335199
7.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

PMID:
20100092
8.

Antiretroviral drug treatment of CNS HIV-1 infection.

Yilmaz A, Price RW, Gisslén M.

J Antimicrob Chemother. 2012 Feb;67(2):299-311. doi: 10.1093/jac/dkr492. Epub 2011 Dec 8. Review.

PMID:
22160207
9.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
10.

Economics of monitoring antiretroviral therapy.

Mermin J, Granich R.

Lancet Infect Dis. 2013 Jul;13(7):560-1. doi: 10.1016/S1473-3099(13)70105-1. Epub 2013 Apr 18. No abstract available.

PMID:
23602085
11.

Stopping antiretroviral therapy: role for therapeutic drug monitoring.

Tommasi C, Nicastri E, Corpolongo A, Ivanovic J, Notari S, Ascenzi P, Andreoni M, Narciso P.

AIDS. 2008 Jan 11;22(2):315-6. No abstract available.

PMID:
18097237
12.

Laboratory monitoring for antiretroviral therapy in low-resource settings.

Boyer S, Laurent C, Kouanfack C, Delaporte E, Moatti JP.

Lancet Infect Dis. 2013 Sep;13(9):739. doi: 10.1016/S1473-3099(13)70203-2. No abstract available.

PMID:
23969214
13.

Evidence gathered from randomized clinical trials and observational studies on the equivalence of emtricitabine and Lamivudine.

Rokx C, Rijnders BJ.

Clin Infect Dis. 2015 Jun 1;60(11):1732-3. doi: 10.1093/cid/civ117. Epub 2015 Feb 16. No abstract available.

PMID:
25690599
14.

[Simplification of the antiretroviral regimens. A need to guarantee the long-term control of HIV infection].

Barreiro García P, Soriano Vázquez V.

Rev Clin Esp. 2004 Apr;204(4):212-4. Spanish. No abstract available.

PMID:
15104931
15.

Viral escape in cerebrospinal fluid--an achilles heel of HIV therapy?

Clifford DB.

J Infect Dis. 2010 Dec 15;202(12):1768-9. doi: 10.1086/657343. Epub 2010 Nov 4. No abstract available.

PMID:
21050117
16.

A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.

Loutfy MR, Genebat M, Moore D, Raboud J, Chan K, Antoniou T, Milan D, Shen A, Klein MB, Cooper C, Machouf N, Rourke SB, Rachlis A, Tsoukas C, Montaner JS, Walmsley SL, Smieja M, Bayoumi A, Mills E, Hogg RS; CANOC Collaboration.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):451-9.

PMID:
21105259
17.

Association between atazanavir plasma levels and renal function in HIV-positive individuals on antiretroviral therapy with undetectable viral load.

Luz AJ, Poeta J, Linden R, Antunes MV, Caminha LI, Callegari-Jacques SM, Sprinz E.

Int J Antimicrob Agents. 2013 May;41(5):497-8. doi: 10.1016/j.ijantimicag.2013.01.013. Epub 2013 Feb 28. No abstract available.

PMID:
23453620
18.

Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agents.

Winston A, Garvey L, Sabin CA.

AIDS. 2011 Apr 24;25(7):1014-5. doi: 10.1097/QAD.0b013e3283454c74. No abstract available.

PMID:
21487256
19.

Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era.

Taffé P, Bucher HC, Flepp M, Battegay M.

AIDS. 2007 Feb 19;21(4):537-8. No abstract available.

PMID:
17301581
20.

[Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].

Sáez-Llorens X, Castrejón de Wong MC, Castaño E, de Suman O, Báez de Ulloa C, Redondo W, Espino M.

Rev Med Panama. 2001;26:13-8. Spanish.

PMID:
16161718

Supplemental Content

Support Center